Biogen, Inc.

( )
BIIB After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
MRNAModerna, Inc. 7.05%349.560.0%$4455.02m
BNTXBioNTech SE 5.96%294.920.0%$826.74m
NVAXNovavax, Inc. 0.59%135.3579.4%$781.84m
AMGNAmgen, Inc. -0.77%207.631.4%$532.33m
REGNRegeneron Pharmaceuticals, Inc. 0.67%576.202.7%$465.16m
SNSSSunesis Pharmaceuticals, Inc. 2.79%6.260.7%$437.60m
CCXIChemoCentryx, Inc. 1.16%34.972.9%$417.40m
GILDGilead Sciences, Inc. 0.64%67.671.0%$400.74m
ILMNIllumina, Inc. 2.84%420.783.3%$364.05m
XLRNAcceleron Pharma, Inc. -0.10%173.785.3%$349.33m
VRTXVertex Pharmaceuticals, Inc. 0.80%184.991.9%$279.73m
BIIBBiogen, Inc. 1.94%269.941.8%$264.88m
OCGNOcugen, Inc. 12.26%9.340.0%$222.68m
XENEXenon Pharmaceuticals, Inc. -0.42%30.730.4%$173.11m
CRSPCRISPR Therapeutics AG 1.19%96.700.6%$165.13m

Company Profile

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.